Selected article for: "cell surface receptor and SARS CoV host cell"
Author: Biswas, Saurav; Thakur, Vikram; Kaur, Parneet; Khan, Azhar; Kulshrestha, Saurabh; Kumar, Pradeep
Title: Blood clots in COVID-19 patients: Simplifying the curious mystery
  • Cord-id: kp114q7n
  • Document date: 2020_11_6
    • ID: kp114q7n
    Snippet: The universal phenomenon of blood clotting is well known to be protective in external cellular/ tissue injury. However, the emergence of unusual thrombotic presentations in COVID-19 patients is the real concern. Interaction of the spike glycoprotein with ACE2 receptor present in the host cell surface mediates the entry of SARS-CoV-2 causing COVID-19 infection. New clinical findings of SARS-CoV-2 pathogenesis are coming out every day, and one such mystery is the formation of mysterious blood clot
    Document: The universal phenomenon of blood clotting is well known to be protective in external cellular/ tissue injury. However, the emergence of unusual thrombotic presentations in COVID-19 patients is the real concern. Interaction of the spike glycoprotein with ACE2 receptor present in the host cell surface mediates the entry of SARS-CoV-2 causing COVID-19 infection. New clinical findings of SARS-CoV-2 pathogenesis are coming out every day, and one such mystery is the formation of mysterious blood clots in the various tissues and organs of COVID-19 patients, which needs critical attention. To address this issue, we hypothesis that, high ACE2 expression in the endothelium of blood vessels facilitates the high-affinity binding of SARS-CoV-2 using spike protein, causing infection and internal injury inside the vascular wall of blood vessels. This viral associated injury may directly/indirectly initiate activation of coagulation and clotting cascades forming internal blood clots. However, the presence of these clots is undesirable as they are responsible for thrombosis and need to be treated with anti-thrombotic intervention.

    Search related documents:
    Co phrase search for related documents
    • acute hepatic and lung pathology: 1
    • acute sars respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and address need: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and adenosine diphosphate: 1, 2
    • acute sars respiratory syndrome coronavirus and adp adenosine diphosphate: 1, 2
    • acute sars respiratory syndrome coronavirus and lung autopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute sars respiratory syndrome coronavirus and lung infect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute sars respiratory syndrome coronavirus and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and lung pathology: 1, 2, 3, 4
    • address need and lung pathology: 1, 2
    • adenosine diphosphate and adp adenosine diphosphate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25